Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.

Yamamoto N, Ryoo BY, Keam B, Kudo M, Lin CC, Kunieda F, Ball HA, Moran D, Komatsu K, Takeda K, Fukuda M, Furuse J, Morita S, Doi T.

Invest New Drugs. 2019 Apr 30. doi: 10.1007/s10637-019-00780-w. [Epub ahead of print]

PMID:
31041575
2.

NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.

Park HR, Ahn YO, Kim TM, Kim S, Kim S, Lee YS, Kim M, Keam B, Kim DW, Heo DS.

Cytotherapy. 2019 Apr 19. pii: S1465-3249(19)30373-1. doi: 10.1016/j.jcyt.2019.03.312. [Epub ahead of print]

PMID:
31010733
3.

Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.

Choi M, Keam B, Ock CY, Kim M, Kim TM, Kim DW, Heo DS.

Clin Lung Cancer. 2019 Mar 29. pii: S1525-7304(19)30078-6. doi: 10.1016/j.cllc.2019.03.005. [Epub ahead of print]

PMID:
31010639
4.

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients.

Choi Y, Keam B, Kim M, Yoon S, Kim D, Choi JG, Seo JY, Park I, Lee JL.

Cancer Res Treat. 2019 Mar 25. doi: 10.4143/crt.2019.086. [Epub ahead of print]

5.

Immune-Checkpoint-Inhibitor-Induced Severe Autoimmune Encephalitis Treated by Steroid and Intravenous Immunoglobulin.

Kim A, Keam B, Cheun H, Lee ST, Gook HS, Han MK.

J Clin Neurol. 2019 Apr;15(2):259-261. doi: 10.3988/jcn.2019.15.2.259. Epub 2019 Mar 11. No abstract available.

6.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.

Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B.

BMC Cancer. 2019 Mar 4;19(1):196. doi: 10.1186/s12885-019-5380-3.

7.

A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.

Keam B, Lee KW, Lee SH, Kim JS, Kim JH, Wu HG, Eom KY, Kim S, Ahn SH, Chung EJ, Kwon SK, Jeong WJ, Jung YH, Kim JW, Heo DS.

Oncologist. 2019 Feb 22. pii: theoncologist.2019-0070. doi: 10.1634/theoncologist.2019-0070. [Epub ahead of print]

PMID:
30796155
8.

Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases.

Chung EJ, Jeong WJ, Jung YH, Kwon SK, Kwon TK, Ahn SH, Sung MW, Keam B, Heo DS, Kim JH, Wu HG, Lee KW, Eom KY, Rho YS.

Oral Oncol. 2019 Feb;89:84-94. doi: 10.1016/j.oraloncology.2018.12.015. Epub 2018 Dec 27.

PMID:
30732965
9.

The Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio before Radical Radiotherapy in Patients with Non-metastatic Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis.

Kim JS, Keam B, Heo DS, Han DH, Rhee CS, Kim JH, Jung KC, Wu HG.

Cancer Res Treat. 2019 Jan 29. doi: 10.4143/crt.2018.503. [Epub ahead of print]

10.

Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.

Jung M, Kim S, Lee JK, Yoon SO, Park HS, Hong SW, Park WS, Kim JE, Kim J, Keam B, Kim HJ, Kang HJ, Kim DW, Jung KC, Kim YT, Heo DS, Kim TM, Jeon YK.

Oncologist. 2019 Jan 29. pii: theoncologist.2018-0477. doi: 10.1634/theoncologist.2018-0477. [Epub ahead of print]

PMID:
30696721
11.

Pruritus in Patients Under Targeted Anticancer Therapy: A Multidimensional Analysis Using the 5-D Itch Scale.

Cho SI, Lee J, Lim J, Park JS, Kim M, Kim TY, Kim TM, Lee KH, Keam B, Han SW, Jo SJ.

Acta Derm Venereol. 2019 Apr 1;99(4):435-441. doi: 10.2340/00015555-3129.

12.

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.

Kim SJ, Kim S, Kim DW, Kim M, Keam B, Kim TM, Lee Y, Koh J, Jeon YK, Heo DS.

Cancer Res Treat. 2018 Dec 31. doi: 10.4143/crt.2018.486. [Epub ahead of print]

13.

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.

Kim R, Keam B, Kim S, Kim M, Kim SH, Kim JW, Kim YJ, Kim TM, Jeon YK, Kim DW, Chung DH, Lee JS, Heo DS.

BMC Cancer. 2019 Jan 7;19(1):19. doi: 10.1186/s12885-018-5214-8.

14.

Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.

Kang SH, Keam B, Ahn YO, Park HR, Kim M, Kim TM, Kim DW, Heo DS.

Oncoimmunology. 2018 Sep 21;8(1):e1515057. doi: 10.1080/2162402X.2018.1515057. eCollection 2019.

PMID:
30546955
15.

Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?

Yoo SH, Ock CY, Keam B, Park SJ, Kim TM, Kim JH, Jeon YK, Chung EJ, Kwon SK, Hah JH, Kwon TK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS.

Korean J Intern Med. 2018 Nov 16. doi: 10.3904/kjim.2017.397. [Epub ahead of print]

16.

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.

Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS.

Cancer Res Treat. 2018 Oct 10. doi: 10.4143/crt.2018.052. [Epub ahead of print]

17.

Optimal timing for salvage surgery after definitive radiotherapy in hypopharyngeal cancer.

Chun SJ, Keam B, Heo DS, Kim KH, Sung MW, Chung EJ, Kim JH, Jung KC, Kim JH, Wu HG.

Radiat Oncol J. 2018 Sep;36(3):192-199. doi: 10.3857/roj.2018.00311. Epub 2018 Sep 30.

18.

Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review.

Cheun H, Kim M, Lee H, Oh KH, Keam B.

Invest New Drugs. 2018 Oct 8. doi: 10.1007/s10637-018-0673-y. [Epub ahead of print]

PMID:
30298302
19.

Significance of 18F-FDG PET Parameters According to Histologic Subtype in the Treatment Outcome of Stage III Non-small-cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy.

Kim E, Wu HG, Keam B, Kim TM, Kim DW, Paeng JC, Kim HJ, Chang JH.

Clin Lung Cancer. 2019 Jan;20(1):e9-e23. doi: 10.1016/j.cllc.2018.08.018. Epub 2018 Aug 30.

PMID:
30266585
20.

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.

Kim M, Kim TM, Keam B, Kim YJ, Paeng JC, Moon KC, Kim DW, Heo DS.

Oncologist. 2019 Jan;24(1):20-e29. doi: 10.1634/theoncologist.2018-0464. Epub 2018 Sep 25.

21.

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity.

Yoo SH, Keam B, Kim M, Kim SH, Kim YJ, Kim TM, Kim DW, Lee JS, Heo DS.

ESMO Open. 2018 Jul 25;3(5):e000332. doi: 10.1136/esmoopen-2018-000332. eCollection 2018.

22.

TRIUMPH Trial: One Small Step Could Become One Giant Leap for Precision Oncology in Head and Neck Cancer.

Keam B, Kim HR, Yun HJ.

Cancer Res Treat. 2019 Jan;51(1):413-414. doi: 10.4143/crt.2018.335. Epub 2018 Jul 31. No abstract available.

23.

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.

Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord JP, Aggarwal R, Gould M, Yang P, Keefe SM, Piha-Paul SA.

Ann Oncol. 2018 Aug 1;29(8):1807-1813. doi: 10.1093/annonc/mdy232.

PMID:
29992241
24.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R.

Br J Cancer. 2018 Jul;119(2):153-159. doi: 10.1038/s41416-018-0131-9. Epub 2018 Jun 29.

PMID:
29955135
25.

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.

Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS.

Korean J Intern Med. 2018 Jun 29. doi: 10.3904/kjim.2018.011. [Epub ahead of print]

26.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF.

Cancer Discov. 2018 Jul;8(7):812-821. doi: 10.1158/2159-8290.CD-18-0229. Epub 2018 May 30.

PMID:
29848605
27.

Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis.

Lee SY, Choi YS, Song IC, Park SG, Keam B, Yang YJ, Song EK, Lee HJ, Cho SH, Shim H, Park KU, Lee KH, Jo DY, Jo IS, Yun HJ; Korean South West Oncology Group (KSWOG) investigators.

Medicine (Baltimore). 2018 May;97(21):e10778. doi: 10.1097/MD.0000000000010778.

28.

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.

Lim SM, Cho SH, Hwang IG, Choi JW, Chang H, Ahn MJ, Park KU, Kim JW, Ko YH, Ahn HK, Cho BC, Nam BH, Chun SH, Hong JH, Kwon JH, Choi JG, Kang EJ, Yun T, Lee KW, Kim JH, Kim JS, Lee HW, Kim MK, Jung D, Kim JE, Keam B, Yun HJ, Kim S, Kim HR.

Cancer Res Treat. 2019 Jan;51(1):300-312. doi: 10.4143/crt.2018.012. Epub 2018 May 9.

29.

Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.

Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS.

Thorac Cancer. 2018 Jun;9(6):736-744. doi: 10.1111/1759-7714.12641. Epub 2018 Apr 22.

30.

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy.

Choi JY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Jo SJ.

Cancer Res Treat. 2019 Jan;51(1):169-177. doi: 10.4143/crt.2017.491. Epub 2018 Apr 5.

31.

Cancer Pain Management Education Rectifies Patients' Misconceptions of Cancer Pain, Reduces Pain, and Improves Quality of Life.

Koh SJ, Keam B, Hyun MK, Ju Seo J, Uk Park K, Oh SY, Ahn J, Lee JY, Kim J.

Pain Med. 2018 Dec 1;19(12):2546-2555. doi: 10.1093/pm/pny039.

PMID:
29590446
32.

Attitudes toward early palliative care in cancer patients and caregivers: a Korean nationwide survey.

Yoo SH, Kim M, Yun YH, Keam B, Kim YA, Kim YJ, Shim HJ, Song EK, Kang JH, Kwon JH, Lee JL, Lee SN, Kim SY, Kang EJ, Do YR, Choi YS, Jung KH.

Cancer Med. 2018 May;7(5):1784-1793. doi: 10.1002/cam4.1441. Epub 2018 Mar 25.

33.

Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance.

Suh KJ, Kim KH, Kim R, Byun JM, Kim M, Park JH, Keam B, Kim TM, Kim JS, Choi IS, Heo DS.

Korean J Intern Med. 2018 Feb 23. doi: 10.3904/kjim.2017.174. [Epub ahead of print]

34.

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B.

Am J Clin Oncol. 2018 Feb 21. doi: 10.1097/COC.0000000000000429. [Epub ahead of print]

35.

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.

Jo J, Kim SH, Kim YJ, Lee J, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Chung JH, Jeon YK, Lee JS.

Yonsei Med J. 2018 Mar;59(2):202-210. doi: 10.3349/ymj.2018.59.2.202.

36.

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.

Park S, Ha S, Lee SH, Paeng JC, Keam B, Kim TM, Kim DW, Heo DS.

PLoS One. 2018 Jan 31;13(1):e0189766. doi: 10.1371/journal.pone.0189766. eCollection 2018.

37.

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K.

Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.

PMID:
29326030
38.

Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.

Tahara M, Muro K, Hasegawa Y, Chung HC, Lin CC, Keam B, Takahashi K, Cheng JD, Bang YJ.

Cancer Sci. 2018 Mar;109(3):771-776. doi: 10.1111/cas.13480. Epub 2018 Feb 8.

39.

The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study.

Lee J, Lim J, Park JS, Kim M, Kim TY, Kim TM, Lee KH, Keam B, Han SW, Mun JH, Cho KH, Jo SJ.

Cancer Res Treat. 2018 Oct;50(4):1186-1193. doi: 10.4143/crt.2017.435. Epub 2017 Dec 14.

40.

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.

Ock CY, Kim S, Keam B, Kim S, Ahn YO, Chung EJ, Kim JH, Kim TM, Kwon SK, Jeon YK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS.

Oncotarget. 2017 Jun 16;8(58):97920-97927. doi: 10.18632/oncotarget.18542. eCollection 2017 Nov 17.

41.

Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.

Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS.

Cancer Immunol Immunother. 2018 Mar;67(3):459-470. doi: 10.1007/s00262-017-2092-x. Epub 2017 Dec 4.

PMID:
29204702
42.

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.

Cho KM, Keam B, Ha H, Kim M, Jung JW, Song WJ, Kim TM, Jeon YK, Kang HR, Kim DW, Kim CW, Heo DS.

Korean J Intern Med. 2017 Nov 20. doi: 10.3904/kjim.2017.036. [Epub ahead of print]

43.

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.

Kim H, Park CM, Keam B, Park SJ, Kim M, Kim TM, Kim DW, Heo DS, Goo JM.

PLoS One. 2017 Nov 3;12(11):e0187500. doi: 10.1371/journal.pone.0187500. eCollection 2017.

44.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B.

J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26.

45.

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.

Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS.

Nat Commun. 2017 Oct 19;8(1):1050. doi: 10.1038/s41467-017-01018-0.

46.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, Rha SY, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T.

Ann Oncol. 2017 Nov 1;28(11):2754-2760. doi: 10.1093/annonc/mdx493.

PMID:
28950297
47.

Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection.

Kim H, Chae KJ, Yoon SH, Kim M, Keam B, Kim TM, Kim DW, Goo JM, Park CM.

Eur Radiol. 2018 Feb;28(2):861-868. doi: 10.1007/s00330-017-5006-6. Epub 2017 Aug 7.

PMID:
28786010
48.

The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer.

Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS.

Cancer Res Treat. 2018 Jul;50(3):720-728. doi: 10.4143/crt.2017.169. Epub 2017 Jul 14.

49.

Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives.

Koh SJ, Kim S, Kim J, Keam B, Heo DS, Lee KH, Kim BS, Kim JH, Chang HJ, Baek SK.

Cancer Res Treat. 2018 Apr;50(2):614-623. doi: 10.4143/crt.2016.446. Epub 2017 Jul 3.

50.

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type.

Kim HJ, Ock CY, Kim TM, Lee SH, Lee JY, Jung SH, Cho YS, Kim M, Keam B, Kim DW, Kim IH, Heo DS.

Cancer Res Treat. 2018 Jul;50(3):670-680. doi: 10.4143/crt.2017.051. Epub 2017 Jul 3.

Supplemental Content

Support Center